Efficacy and safety of anlotinib combined with PD ‐1/ PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
Cancer Medicine · 2023-03 · 12 (5) · 5372-5383
DOI: 10.1002/cam4.5360 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 17.10.2022. Verfasst von Lian Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Immunological, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Chest Hospital.
Abstract (Originalsprache)
Objectives
Treatments for advanced small‐cell lung cancer (SCLC) patients who are resistant to first‐line chemotherapy are limited. Given that antiangiogenic agents and immune‐checkpoint inhibitors (ICIs) can confer synergistic therapeutic benefits, combination therapy should be considered. We explored the efficacy and safety of combination therapy with anlotinib and programmed cell death protein 1 (PD‐1)/programmed cell death‐ligand 1 (PD‐L1) inhibitors as second‐line and subsequent therapy for advanced SCLC. Materials and Methods We reviewed advanced SCLC patients at Shanghai Chest Hospital who had received anlotinib in combination with ICIs from November 2016 to November 2020 as second‐ and subsequent‐line treatment. Patients with advanced SCLC who had received paclitaxel monotherapy as second‐line treatment were included as the control group.
Results
A total of 141 patients were included in the final analysis (40 in the combination therapy group and 101 in the paclitaxel monotherapy group). The median progression‐free survival (PFS) times for the combination therapy and paclitaxel monotherapy groups were 3.40 and 2.83 months ( p = 0.022), respectively, while the median overall survival (OS) times for the combination therapy and paclitaxel monotherapy groups were 8.20 and 5.87 months ( p = 0.048), respectively. Hypertension and hepatic dysfunction were the most pronounced adverse events of combination therapy and two patients changed regimens due to severe fatigue and anorexia.
Conclusion
The combination of anlotinib and PD‐1/PD‐L1 blockade has promising efficacy and safety as a second‐line or subsequent therapy for SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
ORCID-Profile: Lian Yu, Baohui Han, Runbo Zhong
Förderung
- Shanghai Chest Hospital
Zitieren
APA
Yu, L., Xu, J., Qiao, R., Han, B., Zhong, H., & Zhong, R. (2023). Efficacy and safety of anlotinib combined with PD ‐1/ PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer. Cancer Medicine, 12(5), 5372-5383. https://doi.org/10.1002/cam4.5360
Vancouver
Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Efficacy and safety of anlotinib combined with PD ‐1/ PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer. Cancer Medicine. 2023;12(5):5372-5383. doi:10.1002/cam4.5360
BibTeX
@article{Yu2023,
author = {Yu, Lian and Xu, Jianlin and Qiao, Rong and Han, Baohui and Zhong, Hua and Zhong, Runbo},
title = {Efficacy and safety of anlotinib combined with PD ‐1/ PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {5},
pages = {5372--5383},
doi = {10.1002/cam4.5360}
}
EUVIMED